透過您的圖書館登入
IP:18.220.163.91
  • 期刊
  • OpenAccess

Successful Treatment of Metastatic Gastrointestinal Stromal Tumors Using Tyrosine Kinase Inhibitor STI571

並列摘要


Gastrointestinal stromal tumors (GISTs) are a group of mesenchymal neoplasms that arise from the connective tissue cells of the gastrointestinal tract. Malignant GISTs are resistant to chemotherapy and radiation therapy. Complete surgical resection is the best way to cure this disease. However, unresectable conditions, multiple metastases, and postoperative recurrences usually happen in patients with malignant GISTs and the prognosis is disappointing. Recent studies about the proto-oncogene c-kit revealed a ray of hope for the treatment of patients with GISTs. KIT (CD117, a growth factor receptor with tyrosine kinase activity) is the product of the c-kit gene, which is detectable in most GISTs. Mutations of the c-kit gene play an important role of the pathogenesis of the tumors. To block the activity of tyrosine kinase using STI571 (signal transduction inhibitor, imatinib mesylate) was proven effective in treating patients with metastatic or recurrent GISTs. We present a case of metastatic gastric GIST which recurred after a debulky operation. Remission of the recurrent lesions was proven after using STI571.

延伸閱讀